Stockscreener 앱 받기
1.321
6.40%
0.071
전일 마감가:
$1.25
열려 있는:
$1.23
하루 거래량:
402.83K
Relative Volume:
0.23
시가총액:
$3.77M
수익:
-
순이익/손실:
$-6.91M
주가수익비율:
-0.4052
EPS:
-3.26
순현금흐름:
$-6.14M
1주 성능:
-20.36%
1개월 성능:
-0.75%
6개월 성능:
-60.53%
1년 성능:
-71.39%
1일 변동 폭
$1.2299
$1.34
1주일 범위
$1.15
$1.67
52주 변동 폭
$1.15
$23.80
Galmed Pharmaceuticals Ltd Stock (GLMD) Company Profile
GLMD을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
GLMD
Galmed Pharmaceuticals Ltd
|
1.34 | 3.77M | 0 | -6.91M | -6.14M | -3.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.01 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
603.22 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
655.86 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
273.48 | 32.98B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.64 | 26.89B | 3.81B | -644.79M | -669.77M | -6.24 |
Galmed Pharmaceuticals Ltd Stock (GLMD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2020-05-22 | 다운그레이드 | B. Riley FBR | Buy → Neutral |
| 2020-02-04 | 개시 | Craig Hallum | Buy |
| 2020-01-30 | 재개 | Cantor Fitzgerald | Overweight |
| 2019-12-02 | 개시 | Canaccord Genuity | Buy |
| 2018-12-12 | 개시 | B. Riley FBR | Buy |
| 2018-08-02 | 재확인 | Maxim Group | Buy |
| 2018-07-13 | 개시 | Stifel | Buy |
| 2018-07-12 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-06-12 | 재확인 | H.C. Wainwright | Buy |
| 2018-03-15 | 업그레이드 | Maxim Group | Hold → Buy |
| 2018-02-14 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2018-02-12 | 재확인 | H.C. Wainwright | Buy |
| 2017-11-15 | 개시 | ROTH Capital | Buy |
| 2017-08-08 | 재확인 | H.C. Wainwright | Buy |
| 2017-07-31 | 재확인 | Maxim Group | Buy |
| 2016-08-01 | 재확인 | Maxim Group | Buy |
| 2016-07-06 | 재개 | ROTH Capital | Buy |
| 2016-03-28 | 재개 | H.C. Wainwright | Buy |
| 2015-06-23 | 개시 | H.C. Wainwright | Buy |
| 2015-05-06 | 개시 | Sun Trust Rbsn Humphrey | Buy |
모두보기
Galmed Pharmaceuticals Ltd 주식(GLMD)의 최신 뉴스
Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) Short Interest Up 41.3% in April - Defense World
Biotech Alert: Searches spiking for these stocks today - Yahoo Finance
Galmed Pharmaceuticals Ltd (GLMD) Clearly Signals Buy-Into the Stock: Don’t ignore the signals - Sete News
Understanding the Risks of Investing in Galmed Pharmaceuticals Ltd (GLMD) - knoxdaily.com
Galmed Pharmaceuticals (NASDAQ:GLMD) Shares Cross Below 200 Day Moving Average – What’s Next? - Defense World
StockNews.com Begins Coverage on Galmed Pharmaceuticals (NASDAQ:GLMD) - Defense World
Galmed Pharmaceuticals (GLMD) Collaborates with VCU to Tackle GI Cancer Drug Resistance - GuruFocus
GLMD’s Stock Market Pendulum: Swinging Between Gains and Losses - investchronicle.com
Understanding GLMD stock ratios for better investment decisions - uspostnews.com
Crude Oil Down 2%; Roper Technologies Increases 2025 Outlook - Benzinga
Is Galmed Pharmaceuticals Ltd (NASDAQ: GLMD) Stock Worth Investing In for High Returns? - Marketing Sentinel
Galmed Signs Term Sheet to Develop New Semaglutide Formulation; Shares Up - marketscreener.com
Galmed (GLMD) Shares Climb Amid Strategic Drug Delivery Development - Stocks Telegraph
Galmed Pharmaceuticals Signs Agreement for Novel Semaglutide Formulation - TipRanks
Galmed (GLMD) Pharmaceuticals Signs Licensing Agreement for Drug - GuruFocus
Galmed Signed Term Sheet For The Development Of Novel Semaglutide Sublingual Formulation - marketscreener.com
Galmed Signed Term Sheet for the Development of Novel Semaglutide Sublingual Formulation - PR Newswire
Press Release Distribution & PR Platform - ACCESS Newswire
Galmed Pharmaceuticals (NASDAQ:GLMD) Coverage Initiated at StockNews.com - Defense World
Galmed partners with VCU to target drug resistance - The Pharma Letter
Galmed Pharmaceuticals Partners with VCU to Combat Drug Resistance in GI Cancers - TipRanks
Galmed Pharmaceuticals Launches VCU Collaboration To Tackle Drug Resistance In Gi Cancers - marketscreener.com
Galmed Pharmaceuticals Launches VCU Collaboration to Tackle Drug Resistance in GI Cancers - PR Newswire
Galmed reports key biomarkers for heart and liver health By Investing.com - Investing.com South Africa
Galmed Pharmaceuticals Unveils New Blood Markers for Aramchol - TipRanks
Galmed reports key biomarkers for heart and liver health - Investing.com
Galmed Unveils Novel Pharmacodynamic Blood Markers for Aramchol, the Most Clinically Advanced SCD1 Inhibitor - Longview News-Journal
Galmed Pharmaceuticals (NASDAQ:GLMD) Now Covered by Analysts at StockNews.com - Defense World
Galmed Pharmaceuticals Reports Positive Results from AM-001 Study of Aramchol Meglumine - TipRanks
Galmed Announces Positive Part 1 Results from the AM-001 Study of Aramchol Meglumine, an Enhanced Formulation of the Most Clinically Advanced SCD1 Inhibitor - PR Newswire
Maxim Group Reiterates “Hold” Rating for Galmed Pharmaceuticals (NASDAQ:GLMD) - Defense World
Galmed Pharmaceuticals (NASDAQ:GLMD) Earns Sell Rating from Analysts at StockNews.com - Defense World
Galmed Phar stock hits 52-week low at $1.32 amid challenges - Investing.com Australia
Galmed Phar stock hits 52-week low at $1.32 amid challenges By Investing.com - Investing.com South Africa
Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2024 - Yahoo Finance
Galmed Pharmaceuticals (NASDAQ:GLMD) Now Covered by StockNews.com - Defense World
Galmed Phar stock hits 52-week low at $1.66 amid challenges - Investing.com India
Galmed Phar stock hits 52-week low at $1.66 amid challenges By Investing.com - Investing.com South Africa
Galmed Pharmaceuticals Secures New Patent for NASH Therapy - TipRanks
Galmed Pharmaceuticals Secures New Patent Grant Extending Aramchol's Patent Protection to 2039, Strengthening Leadership in NASH/MASH Combination Therapy - PR Newswire
Galmed Pharmaceuticals (NASDAQ:GLMD) Coverage Initiated by Analysts at StockNews.com - Defense World
Can Galmed Pharmaceuticals Ltd (GLMD) meet market expectations this quarter? - uspostnews.com
Galmed Phar stock hits 52-week low at $1.75 amid challenges - Investing.com Australia
Galmed Phar stock hits 52-week low at $1.75 amid challenges By Investing.com - Investing.com South Africa
Galmed Pharmaceuticals (NASDAQ:GLMD) Share Price Passes Below Two Hundred Day Moving Average – Here’s What Happened - Defense World
Galmed Pharmaceuticals Ltd. to Host Earnings Call - ACCESS Newswire
Galmed Phar stock hits 52-week low at $2.21 amid challenges - Investing.com Australia
Galmed Phar stock hits 52-week low at $2.21 amid challenges By Investing.com - Investing.com South Africa
Galmed Pharmaceuticals Ltd (GLMD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.52%
0.52%
자본화:
|
볼륨(24시간):